Factor VIII (medication)
(Redirected from Afstyla)
Factor VIII (also known as Antihemophilic Factor or AHF) is a blood clotting protein that is essential for the normal clotting of blood. It is used as a medication to treat and prevent bleeding in individuals with hemophilia A, a genetic disorder characterized by a deficiency in Factor VIII.
Structure and Function[edit | edit source]
Factor VIII is a large glycoprotein that is synthesized in the liver. It is an essential component of the coagulation cascade, a series of reactions that occur in the body to stop bleeding. Factor VIII acts as a cofactor for Factor IX, enhancing its ability to convert Factor X into its active form, Factor Xa. This is a critical step in the formation of a blood clot.
Medical Use[edit | edit source]
Factor VIII is used as a medication in the treatment of hemophilia A. It is administered intravenously, either as a preventative measure to reduce the risk of bleeding, or to control active bleeding episodes. The dose and frequency of administration depend on the severity of the Factor VIII deficiency, the location and extent of bleeding, and the patient's clinical condition.
Side Effects[edit | edit source]
Like all medications, Factor VIII can cause side effects. These may include allergic reactions, development of inhibitors (antibodies that neutralize the effect of Factor VIII), and transmission of infectious agents if the Factor VIII is derived from human blood.
Production[edit | edit source]
Factor VIII used for therapeutic purposes can be derived from human blood, or it can be produced in a laboratory using recombinant DNA technology. Recombinant Factor VIII is considered safer as it carries no risk of transmitting infectious diseases.
History[edit | edit source]
The role of Factor VIII in blood clotting was first identified in the early 20th century. The use of Factor VIII as a treatment for hemophilia A began in the 1960s, with the development of methods to extract it from human blood. The introduction of recombinant Factor VIII in the 1990s significantly improved the safety and availability of this treatment.
See Also[edit | edit source]
 | This medical article is a stub. You can help WikiMD by expanding it. |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
